Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial

Lancet

Volumn 360, Issue 9347, 2002, Pages 1715-1721

  Green, Ruth H ^a   Brightling, Christopher E ^a   McKenna, Susan ^a   Hargadon, Beverley ^a   Parker, Debbie ^a   Bradding, Peter ^a   Wardlaw, Andrew J ^a   Pavord, Ian D ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PREDNISOLONE; SALBUTAMOL; THEOPHYLLINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; TREATMENT OUTCOME;

EID: 0037202790     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11679-5     Document Type: Article

References (32)

1. Wardlaw A.J., Brightling C., Green R., Woltmann G., Pavord I. Eosinophils in asthma and other allergic diseases. Br Med Bull. 56:2000;985-1003.
2. Janson C., Chinn S., Jarvis D., Burney P. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J. 10:1997;1795-1802.
3. Campbell M.J., Cogman G.R., Holgate S.T., Johnston S.L. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ. 314:1997;1439-1441.
4. The British guidelines on asthma management. Thorax. 52:(suppl):1997;S1-S20.
5. Crimi E., Spanevello A., Neri M., Ind P.W., Rossi G.A., Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med. 157:1998;4-9.
6. Parameswaran K., Pizzichini E., Pizzichini M.M., Hussack P., Efthimiadis A., Hargreave F.E. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. Eur Respir J. 15:2000;486-490.
7. Leckie M.J., ten Brinke A., Khan J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2000;2144-2148.
8. Pizzichini M.M., Pizzichini E., Clelland L., et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J. 13:1999;15-21.
9. Jatakanon A., Lim S., Barnes P.J. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 161:2000;64-72.
10. Pavord I.D., Pizzichini M.M., Pizzichini E., Hargreave F.E. The use of induced sputum to investigate airway inflammation. Thorax. 52:1997;498-501.
11. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 337:1997;1405-1411.
12. Treasure T., MacRae K.D. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ. 317:1998;362-363.
13. Pavord I.D., Brightling C.E., Woltmann G., Wardlaw A.J. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 353:1999;2213-2214.
14. Green R.H., Brightling C.E., Vara D.D., Parker D., Wardlaw A.J., Pavord I.D. The relationship between eosinophilic airway inflammation and exhaled nitric oxide in asthma. Eur Respir J. 16:(suppl):2000;7S.
15. Turner M.O., Johnston P.R., Pizzichini E., Pizzichini M.M., Hussack P.A., Hargreave F.E. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J. 5:1998;261-268.
16. Louis R., Bettiol J., Cataldo D., Sele J., Henquet M., Radermecker M. Effect of a 4-week treatment with theophylline on sputum eosinophilia and sputum eosinophil chemotactic activity in steroid-naive asthmatics. Clin Exp Allergy. 30:2000;1151-1160.
17. Pizzichini E., Leff J.A., Reiss T.F., et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J. 14:1999;12-18.
18. Juniper E.F., Guyatt G.H., Ferrie P.J., Griffith L.E. Measuring quality of life in asthma. Am Rev Respir Dis. 147:1993;832-838.
19. Kharitonov S., Alving K., Barnes P.J. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J. 10:1997;1683-1693.
20. Juniper E.F., Cockcroft D.W., Hargreave F.E. Histamine and methacholine inhalation tests: a laboratory tidal breathing protocol. 2nd edn :1994;Astra Draco AB, Lund, Sweden.
21. Netton A, Rees T, Harrison G. Unit Costs of Health and Social Care 2001. Kent, UK: Personal Social Services Research Unit, 2001. http://www.ukc.ac.uk/PSSRU/ (accessed May, 2002).
22. NHS. The new NHS - 2001 Reference Costs. London, UK: Department of Health, 2001. http://www.doh.gov.uk/nhsexec/refcosts.htm (accessed May, 2002).
23. Thompson S.G., Barber J.A. How should cost data in pragmatic randomised trials be analysed? BMJ. 320:2000;1197-1200.
24. Hoskins G., McCowan C., Neville R.G., Thomas G.E., Smith B., Silverman S. Risk factors and costs associated with an asthma attack. Thorax. 55:2000;19-24.
25. Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., Pavord I.D. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 346:2002;1699-1705.
26. Carroll N., Carello S., Cooke C., James A. Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J. 9:1996;709-715.
27. Reddel H., Ware S., Marks G., Salome C., Jenkins C., Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet. 353:1999;364-369.
28. Sont J.K., Willems L.N., Bel E.H., van Krieken J.H., Vandenbroucke J.P., Sterk P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med. 159:1999;1043-1051.
29. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 162:2000;2341-2351.
30. Wenzel S.E., Schwartz L.B., Langmack E.L., et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 160:1999;1001-1008.
31. Gibson P.G., Simpson J.L., Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 119:2001;1329-1336.
32. Veen J.C., Smits H.H., Ravensberg A.J., Hiemstra P.S., Sterk P.J., Bel E.H. Impaired perception of dyspnea in patients with severe asthma. Relation to sputum eosinophils. Am J Respir Crit Care Med. 158:1998;1134-1141.